Filtered By:
Cancer: Brain Cancers
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 20131 results found since Jan 2013.
DNA is Better at Math than You Are
By KIM BELLARD
I was tempted to write about the work being done at Wharton that suggests that AI may already be better at being entrepreneurial than most of us, and of course I’m always interested to see how nanoparticles are starting to change health care (e.g., breast cancer or cancer more generally), but when I saw what researchers at China’s Shanghai Jiao Tong University have done with DNA-based computers, well, I couldn’t pass that up.
If PCs helped change the image of computers from the big mainframes, and mobile phones further redefined what a computer is, then DNA computers may cause us to one day...
Source: The Health Care Blog - September 20, 2023 Category: Consumer Health News Authors: matthew holt Tags: Health Tech DNA Future of Computing Kim Bellard Source Type: blogs
Cancers, Vol. 15, Pages 4651: Is Insulin Receptor Substrate4 (IRS4) a Platform Involved in the Activation of Several Oncogenes?
Miguel A. Ortega
The IRS (insulin receptor substrate) family of scaffold proteins includes insulin receptor substrate-4 (IRS4), which is expressed only in a few cell lines, including human kidney, brain, liver, and thymus and some cell lines. Its N-terminus carries a phosphotyrosine-binding (PTB) domain and a pleckstrin homology domain (PH), which distinguishes it as a member of this family. In this paper, we collected data about the molecular mechanisms that explain the relevance of IRS4 in the development of cancer and identify IRS4 differences that distinguish it from IRS1 and IRS2. Search engines and different dat...
Source: Cancers - September 20, 2023 Category: Cancer & Oncology Authors: Luis G. Guijarro Francisco Javier Justo Bermejo Diego Liviu Boaru Patricia De Castro-Martinez Diego De Leon-Oliva Oscar Fraile-Mart ínez Cielo Garcia-Montero Melchor Alvarez-Mon Mar ía del Val Toledo-Lobo Miguel A. Ortega Tags: Review Source Type: research
Nanotube breakthroughs: unveiling the potential of carbon nanotubes as a dual therapeutic arsenal for Alzheimer ’s disease and brain tumors
Alzheimer’s disease (AD) and brain tumors are debilitating neurological conditions that pose significant challenges in current medical practices. Existing treatment options for AD primarily focus on symptom management, and brain tumors often require aggressive therapeutic approaches. Novel disease-modifying strategies and therapeutic agents are urgently needed to address the underlying causes of AD pathogenesis and improve brain tumor management. In recent years, nanoparticles (NPs) have shown promise as valuable tools in diagnosing and managing various brain disorders, including AD. Among these, carbon nanotubes (CNTs) ...
Source: Frontiers in Oncology - September 20, 2023 Category: Cancer & Oncology Source Type: research
Proteomic landscape of primary and metastatic brain tumors for heterogeneity discovery
CONCLUSIONS AND CLINICAL RELEVANCE: We characterized an extensive proteomic landscape of BrMs and gliomas. These findings have promising implications for the development of targeted therapies for BrMs and gliomas.PMID:37726528 | DOI:10.1002/prca.202300010
Source: Clinical Lung Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Shuang Yang Chengbin Zhou Lei Zhang Yueting Xiong Yongtao Zheng Liuguan Bian Xiaohui Liu Source Type: research
Advanced age in humans and mouse models of glioblastoma show decreased survival from extratumoral influence
CONCLUSIONS: This work suggests a potential benefit for combining senolytics with immunotherapy in older patients with GBM.PMID:37725593 | DOI:10.1158/1078-0432.CCR-23-0834
Source: Clinical Cancer Research - September 19, 2023 Category: Cancer & Oncology Authors: Margaret Johnson April Bell Kristen L Lauing Erik Ladomersky Lijie Zhai Manon Penco-Campillo Yajas Shah Elizabeth Mauer Joanne Xiu Theodore Nicolaides Michael Drumm Kathleen McCortney Olivier Elemento Miri Kim Prashant Bommi Justin T Low Ruba Memon Jennif Source Type: research
Proteomic landscape of primary and metastatic brain tumors for heterogeneity discovery
CONCLUSIONS AND CLINICAL RELEVANCE: We characterized an extensive proteomic landscape of BrMs and gliomas. These findings have promising implications for the development of targeted therapies for BrMs and gliomas.PMID:37726528 | DOI:10.1002/prca.202300010
Source: Clinical Breast Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Shuang Yang Chengbin Zhou Lei Zhang Yueting Xiong Yongtao Zheng Liuguan Bian Xiaohui Liu Source Type: research
Improved survival and intracranial tumor control of EGFR-mutated NSCLC patients with newly developed brain metastases following stereotactic radiosurgery and EGFR-TKI: a large retrospective cohort study and meta-analyses
CONCLUSIONS: Combined SRS and TKI resulted in favorable outcomes in EGFR-mutated NSCLC patients with newly diagnosed BMs. Continuation of the same TKI agent plus SRS in case of new brain metastases yielded good clinical outcomes and may be considered a standard-of-care treatment.PMID:37721662 | DOI:10.1007/s11060-023-04452-x
Source: Cancer Control - September 18, 2023 Category: Cancer & Oncology Authors: Ai Seon Kuan Chi-Lu Chiang Hsiu-Mei Wu Huai-Che Yang Ching-Jen Chen Chung-Jung Lin Wan-Yuo Guo David Hung-Chi Pan Wen-Yuh Chung Cheng-Chia Lee Source Type: research
Assessing the prognostic value of IMDC risk score for nivolumab-treated patients with renal cancer and malignant melanoma
CONCLUSION: In our study, the IMDC was confirmed to be a prognostic factor for MM. The IMDC groups were similar, except for the favorable RCC and MM groups. Different metastatic sites were prognostic, similar to the IMDC risk group in the MM group.PMID:37718781 | DOI:10.3233/CBM-230159
Source: Cancer Biomarkers : Section A of Disease Markers - September 18, 2023 Category: Cancer & Oncology Authors: Ismail Beyp ınar Y ıldız Sözel Arif Hakan Önder Source Type: research
